Opinion
Video
Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.
EP: 1.Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer
EP: 2.Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
EP: 3.Evolving Treatment Paradigm and NCCN Guideline Updates
EP: 4.The EMBARK trial investigating enzalutamide in NM CSPC
EP: 5.The Role of PSA Doubling Time in Risk Assessment
Now Viewing
EP: 6.Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
EP: 7.Patient Case 2: Metastatic CSPC
EP: 8.Final Thoughts on CSPC
- Efstathiou: What are your impressions of the patient case? How would you evaluate and risk stratify this patient?
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
